ライフサイエンスコーパス: NMSC

1 NMSC and melanoma skin cancers were ascertained by annua

2 NMSC cases arising from patients served by a staff model

3 NMSC patients diagnosed between January 1, 1988, and Dec

4 NMSC patients were defined by a history of basal cell or

5 melanoma, corresponding to more than 450 000 NMSC cases and more than 10 000 melanoma cases each year

6 : 2.54; 95% CI: 0.95, 6.81; P-trend = 0.03), NMSC (HR(T3vs.T1): 3.49; 95% CI: 1.11, 11.0; P-trend = 0

7 : 1.79; 95% CI: 1.07, 2.99; P-trend = 0.03], NMSC (HR(T3vs.T1): 1.85; 95% CI: 1.06, 3.23; P-trend = 0

8 ons 18 years or older who had had at least 1 NMSC during the 1996-2008 period.

9 health care plan, diagnosed with at least 1 NMSC from 1996-2008 to determine risk of subsequent NMSC

10 the original cohort to those with at least 1 NMSC.

11 screen for isolates of ET-24 by testing 199 NMSC isolates of 51 different ETs.

12 A 6-year retrospective review of 2998 NMSC cases between February 26, 2007, and February 17, 2

13 es of data from 1988-2007 ascertained 11,742 NMSC patients.

14 Of all 2998 cases, we identified 805 NMSC-ASE cases: 137 IS and 668 IC.

15 ect of these drugs on the risk of additional NMSCs.

16 tions were identified by using 3 algorithms: NMSC International Classification of Diseases, Ninth Rev

17 supergene family is associated with altered NMSC risk in nontransplant patients, we examined allelis

18 that significantly increased the odds of an NMSC diagnosis were light skin color (OR, 5.79 [95% CI,

19 ppression increases the risk of melanoma and NMSC among patients with IBD.

20 The risk of melanoma and NMSC was evaluated by incidence rate ratio (IRR) and by

21 partly reflecting an ageing population, and NMSC is more commonly seen in men.

22 They also suggest sunburn and NMSC etiologies are immunologically linked.

23 between photosensitizing medication use and NMSC.

24 965 cases was selected for chart review, and NMSCs were validated in 47.0% of ICD-9-CM-identified pat

25 lidation of administrative data to ascertain NMSC demonstrates respectable sensitivity and specificit

26 administrative data can be used to ascertain NMSC with high positive predictive values with either IC

27 be used as sampling frames for ascertaining NMSC.

28 Because NMSCs are rarely lethal and most cancer registries do no

29 Associations were measured between NMSC and 221 SNPs in 26 NER genes.

30 In both NMSC and bladder tumors we found a high prevalence of EM

31 This association was primarily driven by NMSC, lymphoma, and lung cancer.

32 Neisseria meningitidis serogroup C (NMSC) isolates of electrophoretic type 24 (ET-24), as id

33 uency of Neisseria meningitidis serogroup C (NMSC) outbreaks in the United States has increased.

34 mtDNA) deletions in nonmelanoma skin cancer (NMSC) and in cutaneous photoaging was explored using a g

35 levels with risk of nonmelanoma skin cancer (NMSC) and melanoma, we evaluated the effects of vitamin

36 , and Australia for nonmelanoma skin cancer (NMSC) and melanoma.

37 B radiation against nonmelanoma skin cancer (NMSC) are exerted via signaling mechanisms involving the

38 DSCMs for residual nonmelanoma skin cancer (NMSC) before and after a brief training session (about 5

39 developed an SN1 of nonmelanoma skin cancer (NMSC) had a cumulative incidence of subsequent malignant

40 Nonmelanoma skin cancer (NMSC) has become the most common type of cancer in many

41 the US incidence of nonmelanoma skin cancer (NMSC) has been difficult.

42 isk of melanoma and nonmelanoma skin cancer (NMSC) in patients with IBD and how medications affect th

43 mortality rates for nonmelanoma skin cancer (NMSC) in the United States.

44 is limited because non-melanoma skin cancer (NMSC) is predominantly formed on body sites which are 'u

45 he incidence of nonmelanomatous skin cancer (NMSC) is substantially higher among renal transplant rec

46 Nonmelanoma skin cancer (NMSC) is the most common cancer worldwide and the most f

47 Non-melanoma skin cancer (NMSC) is the most common malignancy, whose public health

48 a periocular region nonmelanoma skin cancer (NMSC) or a nonperiocular NMSC causing a complication req

49 pected incidence of nonmelanoma skin cancer (NMSC) or other cancers, whereas those receiving combinat

50 Non-melanoma skin cancer (NMSC) represents a significant cause of morbidity and mo

51 linical marker for non-melanoma skin cancer (NMSC) risk.

52 in a series of 61 non-melanoma skin cancer (NMSC) tumors.

53 nt cancer excluding nonmelanoma skin cancer (NMSC) were 1.06 (95% CI, 1.02-1.09), 1.06 (95% CI, 1.02-

54 a (typically called nonmelanoma skin cancer (NMSC)).

55 high incidence of non-melanoma skin cancer (NMSC), a preventative intervention would be desirable.

56 n cancer (overall), nonmelanoma skin cancer (NMSC), and basal cell carcinoma (BCC).

57 the development of non-melanoma skin cancer (NMSC), controlling for known confounders.

58 infected persons of nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamou

59 the development of non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous

60 t options exist for nonmelanoma skin cancer (NMSC), including topical agents, surgery, or definitive

61 ographic surgery of nonmelanoma skin cancer (NMSC), inflammation in histologic frozen sections has be

62 s a risk factor for nonmelanoma skin cancer (NMSC), particularly squamous cell tumors.

63 and categorized as nonmelanoma skin cancer (NMSC), viral-linked and "other" cancers.

64 counted, except for nonmelanoma skin cancer (NMSC), where only the first was counted.

65 et B (UVB)-induced non-melanoma skin cancer (NMSC), which consists primarily of squamous cell carcino

66 susceptibility to non-melanoma skin cancer (NMSC).

67 es for ascertaining nonmelanoma skin cancer (NMSC).

68 decreased risk of non-melanoma skin cancer (NMSC).

69 and progression of nonmelanoma skin cancer (NMSC).

70 for developing nonmelanomatous skin cancer (NMSC).

71 s cancers following nonmelanoma skin cancer (NMSC).

72 uding and excluding nonmelanoma skin cancer (NMSC); all malignancies were externally adjudicated.

73 f 191 patients with nonmelanoma skin cancer (NMSC; 81 SCC and 110 basal cell carcinoma (BCC)) and 176

74 .04, 0.02, and 0.02 for overall skin cancer, NMSC, and BCC, respectively.

75 n and increased risk of overall skin cancer, NMSC, and BCC.

76 Nonmelanoma skin cancers (NMSC) are among the most common malignancies in the worl

77 be carcinogenic in nonmelanoma skin cancers (NMSC), but the basis for potential viral contributions t

78 es usually exclude nonmelanoma skin cancers (NMSC), despite the large population affected.

79 ity and number of non-melanoma skin cancers (NMSCs) among 10 183 European Americans in the discovery

80 Non-melanoma skin cancers (NMSCs) are among the most common human malignancies.

81 Nonmelanoma skin cancers (NMSCs) are the most common cancers in fair-skinned popul

82 Non-melanoma skin cancers (NMSCs) are the most common malignancy among US Caucasian

83 s cell carcinomas (nonmelanoma skin cancers (NMSCs)), data are insufficient to permit evidence-based

84 initiation of some nonmelanoma skin cancers (NMSCs), particularly in patients with the genetic disord

85 for primary facial nonmelanoma skin cancers (NMSCs), recurrence rates with Mohs micrographic surgery

86 risk of developing nonmelanoma skin cancers (NMSCs).

87 bo, respectively), nonmelanoma skin cancers (NMSCs; four vs. zero squamous cell carcinomas (SCCs)), a

88 yelinating and nonmyelinating Schwann cells (NMSCs) of transgenic mice.

89 ion, Clinical Modification (ICD-9-CM) codes, NMSC treatment Current Procedural Terminology (CPT) code

90 e chose 66 isolates from four well-described NMSC outbreaks that occurred in the United States from 1

91 ly improved accuracy and precision to detect NMSC.

92 by sensitivity and specificity of detecting NMSC using DSCMs vs standard frozen histopathologic spec

93 sensitivities and specificities of detecting NMSC were 90% (95% CI, 89%-91%) and 79% (95% CI, 52%-100

94 Not all immunosuppressed patients develop NMSC, however, and in those that do, the rate of accrual

95 the BsmI SNP were twice as likely to develop NMSC than participants with no mutation (OR, 2.04 [95% C

96 One hundred six (4.3%) patients developed NMSC between 1984 and 1997.

97 d with RT are at highest risk for developing NMSC.

98 patients are at increased risk of developing NMSCs with aggressive subclinical extensions (NMSC-ASE),

99 al Care Survey database was used to estimate NMSC-related office visits for 2012.

100 Age-standardized (Europe) NMSC incidence was 119/100,000 for women and 145/100,000

101 nt neoplasm (SMN; ie, malignancies excluding NMSC) of 20.3% (95% CI, 13.0% to 27.6%) at 15 years comp

102 I, 0.71-1.36) for all malignancies excluding NMSC.

103 I, 0.83-1.59) for all malignancies excluding NMSC.

104 2.78-6.59) and for any malignancy excluding NMSC (SIR, 4.16; 95% CI, 1.67-8.57).

105 and whose SN1 was an invasive SMN (excluding NMSC).

106 MSCs with aggressive subclinical extensions (NMSC-ASE), which may extend aggressively far beyond conv

107 ocular sequelae due to nonperiocular facial NMSC.

108 rticipants entered the cohort at their first NMSC diagnosis and were observed through 2008.

109 nal attributable risk were 3.0% to 21.8% for NMSC and 2.6% to 9.4% for melanoma, corresponding to mor

110 .15-1.49), and 1.89 (95% CI, 1.25-2.86); for NMSC, 1.12 (95% CI, 1.07-1.16), 1.09 (95% CI, 1.05-1.13)

111 ese findings have important implications for NMSC screening and prevention.

112 ignificantly elevated SIRs were observed for NMSC and NHL in those treated with immunosuppressive age

113 s been described as a noninvasive option for NMSC.

114 ber of persons with at least 1 procedure for NMSC increased by 14% (from 1,177,618 to 1,336,800) from

115 The age-adjusted US mortality rate for NMSC arising on nongenital skin from 1969 to 2000 was 0.

116 e patients that are at an increased risk for NMSC and who may therefore be good candidates for preven

117 of this study suggest an increased risk for NMSC-ASE lesions in IS patients, especially in SOTRs and

118 e polymorphisms increase a person's risk for NMSC.

119 dures in Medicare beneficiaries specific for NMSC increased by 14% from 1,918,340 in 2006 to 2,191,10

120 We conclude that, for NMSC, quality-of-life outcomes were similar after excisi

121 of persons in the United States treated for NMSC at 3,315,554.

122 e quality-of-life outcomes of treatments for NMSC.

123 Positive predictive values for NMSC ascertainment were calculated.

124 may be effective chemopreventive agents for NMSCs.

125 ese data indicate that common treatments for NMSCs were at least 95% effective, and further studies a

126 tumor-free "margin" skin were obtained from NMSC patients undergoing excision and the mtDNA from the

127 be placed on reducing mortality from genital NMSC while continuing to stress reduction of excess sun

128 We evaluated the odds ratio of having NMSC-ASE lesions in IS patients (SOTRs, HIV, hematologic

129 er mean daily UVR was associated with higher NMSC incidence rates; this was greater in men than women

130 of UVB-induced SCC and BCC, as well as human NMSC from sun-exposed sites, to investigate the expressi

131 In NMSC the prevalence of EMAST was higher in tumors that h

132 There was a decline (P<0.001) in NMSC 10-year cumulative incidence rate in RTRs over the

133 recent advances, and areas of controversy in NMSC and Merkel cell carcinoma of the head and neck.

134 on against oxidative stress are important in NMSC development in immunosuppressed patients and may be

135 TLA4 locus may be etiologically important in NMSC, the most prevalent malignancy in the United States

136 ure levels, UVB confers a modest increase in NMSC risk, much less than that observed with PUVA.

137 n development are not considered relevant in NMSC etiology, and remain poorly investigated.

138 Appropriate modeling of incidence trends in NMSC among RTRs is a valuable surveillance exercise for

139 approach was used to estimate the trends in NMSC rates that adjusted for changes in the RTR populati

140 of UVR explained most of the variability in NMSC incidence: 82% for basal cell carcinoma (BCC) and 8

141 arch into unexplained regional variations in NMSC incidence.

142 Neither incident NMSC nor melanoma rates differed between treatment (haza

143 , abatacept, or rituximab after the incident NMSC surgery.

144 occurring 1 year or more after the incident NMSC using Cox proportional hazards regression models.

145 rituximab were not associated with increased NMSC risk.

146 4-NQO reflects susceptibility to UV-induced NMSC.

147 t MIF plays an important role in UVB-induced NMSC development and progression.

148 nsory pain pathway primarily via influencing NMSC function, which in turn modulates the structure and

149 sarcoma and nonmelanotic skin malignancies (NMSC) frequently undergo remission/regression after conv

150 In contrast to nongenital NMSC, mortality rates among black men were twice that of

151 lanoma skin cancer (NMSC) or a nonperiocular NMSC causing a complication requiring eyelid surgery wer

152 s; and type of NMSC, number of nonperiocular NMSCs, ophthalmologic findings, and periocular sequelae

153 I had three times the incidence (P<0.001) of NMSC compared with NI.

154 lative risk, 2.82; 95% CI, 1.07-7.44) and of NMSC (relative risk, 3.46; 95% CI, 1.08-11.06).

155 confidence interval [CI], 1.66-5.10) and of NMSC (standardized incidence ratio, 4.59; 95% CI, 2.51-7

156 Histologically confirmed cases of NMSC (n=900) were matched to controls (n=900) on the bas

157 Of the medical records of 3148 cases of NMSC that were reviewed, 60 showed inflammation in histo

158 Cases of NMSC were confirmed in 96.5% of ICD-9-CM-identified pati

159 o UV radiation (UVR) is the primary cause of NMSC, although the pattern of exposure that gives rise t

160 screen use, the quest for chemoprevention of NMSC in the general population has been unsuccessful.

161 gene are associated with the development of NMSC and the demographic characteristics of the particip

162 population to facilitate early diagnosis of NMSC and reduction in sun exposure.

163 espective cancer registries for diagnosis of NMSC, mainly squamous cell carcinoma (SCC) and basal cel

164 tions associated with the staged excision of NMSC was performed from September 8, 2008, to September

165 The risk factors of family history of NMSC (OR, 1.66 [95% CI, 0.90-3.07]) and light hair color

166 Persons with a history of NMSC are at increased risk of cancer mortality.

167 In subgroup analyses, women with history of NMSC assigned to CaD had a reduced risk of melanoma vers

168 logical mechanisms are unknown, a history of NMSC should increase the clinician's alertness for certa

169 entional risk factors, a baseline history of NMSC was associated with increased total cancer mortalit

170 However, in women with history of NMSC, CaD supplementation reduced melanoma risk, suggest

171 For patients with a history of NMSC, data are limited on the effect of these drugs on t

172 was not observed in women without history of NMSC.

173 The incidence of NMSC also increased among patients with IBD (IRR, 1.46;

174 ough nationwide estimate of the incidence of NMSC and provides evidence of continued increases in num

175 Incidence of NMSC in the US population in 2012 and BCC and SCC in the

176 The incidence of NMSC in white populations worldwide as reported in popul

177 provided age- and sex-specific incidence of NMSC in white populations worldwide was systematically r

178 cium did not reduce the overall incidence of NMSC or melanoma.

179 s, there was an increase in the incidence of NMSC with time since transplantation.

180 Location of NMSC included head and neck (43%), back (24%), chest (22

181 esis, may be involved in the pathogenesis of NMSC.

182 port a role for bcl-2 in the pathogenesis of NMSC.

183 between BCC and SCC and allow prediction of NMSC incidence for data-poor regions and under changing

184 Statistically significant predictors of NMSC-ASE lesions such as age, location, and IS status ca

185 ful in the early treatment and prevention of NMSC with chemopreventive agents (for those with the Bsm

186 of MIF in the development and progression of NMSC, we exposed MIF(-/-) BALB/c mice to acute and chron

187 s been identified as a critical regulator of NMSC.

188 gs was significantly associated with risk of NMSC (HR, 1.49; 95% CI, 1.03-2.16).

189 ed with thiopurines had an increased risk of NMSC (OR, 1.85; 95% CI, 1.66-2.05).

190 mab was associated with an increased risk of NMSC and other cancers.

191 Adjusted for other medications, the risk of NMSC increased with 1 year or more of methotrexate use (

192 creased by use of biologics, and the risk of NMSC is increased by use of thiopurines.

193 may be associated with an increased risk of NMSC that may be specific to BCC.

194 nificantly associated with increased risk of NMSC: rs2228527 (odds ratio (OR) 1.57, 95% confidence in

195 SN1 of NMSC identifies a population at high risk for invasive S

196 Using a population-based study of NMSC we found that oral steroid use is associated with n

197 carcinoma (SCC) of the skin is a subtype of NMSC that shows a greater potential for invasion and met

198 During Mohs micrographic surgery of NMSC with the examination of frozen sections, histologic

199 ve agents received at diagnosis; and type of NMSC, number of nonperiocular NMSCs, ophthalmologic find

200 posure that gives rise to different types of NMSC appears to vary.

201 luence odds of developing the major types of NMSC, basal cell carcinoma (BCC) and squamous cell carci

202 -2 expression may prevent the development of NMSCs.

203 ciatic nerves; however, there was no loss of NMSCs that ensheathe these axons.

204 We estimate the total number of NMSCs in the US population in 2012 at 5,434,193 and the

205 As for the number of NMSCs, we identified two independent SNPs on chr6 and on

206 The impact of screening on NMSC incidence in Schleswig-Holstein, Germany, is analyz

207 The impact of screening on NMSC incidence in Schleswig-Holstein, Germany, is analyz

208 sed the effects of 0.1% topical tretinoin on NMSC.

209 e-control studies, patients with melanoma or NMSC were matched to 4 patients with IBD without melanom

210 d to 4 patients with IBD without melanoma or NMSC.

211 nsplant follow-up, and background population NMSC incidence rates.

212 ociation between HLA type and posttransplant NMSC in 2,433 renal-transplant recipients in a Northern

213 7 157 recipients, by 3 years posttransplant, NMSC was diagnosed in 5.7%, viral-linked cancer in 1.9%,

214 A model was created to predict NMSC diagnoses using known risk factors and, potentially

215 n = 355) without having a subsequent primary NMSC.

216 t study of consecutive patients with primary NMSCs treated with the most common treatments, in two pr

217 Individuals with a prior NMSC history are at increased risk for subsequent NMSC,

218 in the dermatology clinic for biopsy-proven NMSC of the head and neck during the study period, and 1

219 ligible CCSS participants, 213 have reported NMSC; 99 patients (46%) have had multiple occurrences.

220 tigation of the 3895 bp deletion in the same NMSC samples used in a previous study of the 4977 bp com

221 ssociated with an increased risk of a second NMSC (hazard ratio [HR], 1.60; 95% CI, 1.08-2.37).

222 nti-TNF do not increase the risk of a second NMSC in patients with IBD.

223 A second NMSC occurring 1 year or more after the incident NMSC us

224 88 with IBD), the incidence rate of a second NMSC per 1000 person-years was 58.2 (95% CI, 54.5-62.1)

225 ti-TNF use may increase the risk of a second NMSC when used with methotrexate for RA.

226 ssociated with an increased risk of a second NMSC.

227 ticle reports on the occurrence of secondary NMSC as a long-term effect of cancer therapy in survivor

228 Measured CD4 count, VL, and subsequent NMSC (BCC and SCC).

229 history are at increased risk for subsequent NMSC, but the magnitude of risk and its relation to HIV

230 s/mL) had a 44% increased risk of subsequent NMSC overall and a 222% increase risk of SCC in particul

231 rogression may be associated with subsequent NMSC risk.

232 om 1996-2008 to determine risk of subsequent NMSCs in relation to CD4 count and VL.

233 d an increased risk of malignancy other than NMSC (relative risk, 2.82; 95% CI, 1.07-7.44) and of NMS

234 xpected incidence of malignancies other than NMSC (standardized incidence ratio, 3.04; 95% confidence

235 nt molecular subtyping standard, most of the NMSC outbreaks have been caused by isolates of several c

236 aths in the United States were attributed to NMSC from 1969 to 2000.

237 A subset of charts was reviewed to verify NMSC diagnosis, including all records from HMO-enrollee

238 sed group, the most common malignancies were NMSC (n = 11) and non-Hodgkin's lymphoma (NHL; n = 4) an

239 er case, followed by "other" cancer, whereas NMSC impacted only outpatient costs.

240 ociations with death and graft loss, whereas NMSC was associated with 33% higher mortality beyond the

241 he identification of factors associated with NMSC diagnosis.

242 se claims data cases were then compared with NMSC identified using natural language processing (NLP)

243 ohort study of 633 consecutive patients with NMSC diagnosed in 1999 and 2000 and followed for 2 years

244 twin studies in nontransplant patients with NMSC suggest a low genetic component, several genes asso

245 ermine the association of polymorphisms with NMSC development and demographic characteristics.